Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors

Oncotarget

Volumn 6, Issue 5, 2015, Pages 3147-3164

  Wang, Zeyou ^a   Yang, Jing ^a   Xu, Gang ^a   Wang, Wei ^a   Liu, Changhong ^a   Yang, Honghui ^a   Yu, Zhibin ^a   Lei, Qianqian ^a   Xiao, Lan ^a   Xiong, Jing ^a,b   Zeng, Liang ^a   Xiang, Juanjuan ^a   Ma, Jian ^a   Li, Guiyuan ^a   Wu, Minghua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chemosensitivity; miRNA; Multidrug resistance factor; Neurofilament light polypeptide; Stemness factor

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; BREAST CANCER RESISTANCE PROTEIN; CELL PROTEIN; HERMES ANTIGEN; KRUPPEL LIKE FACTOR 4; LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 381; MICRORNA 381 ANTIBODY; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 5; NESTIN; NEUROFILAMENT LIGHT POLYPEPTIDE; POLYPEPTIDE; RNA ANTIBODY; SMALL INTERFERING RNA; STEM CELL FACTOR; STEMNESS FACTOR; TEMOZOLOMIDE; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; MIRN381 MICRORNA, HUMAN; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN L;

ARTICLE; ASTROCYTOMA; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; FLUORESCENCE ANALYSIS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN RNA BINDING; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE; TWO DIMENSIONAL FLUORESCENCE DIFFERENTIAL GEL ELECTROPHORESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; U251 CELL LINE; UPREGULATION; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CANCER STEM CELL; CELL MOTION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PROCEDURES; PROTEOMICS; RNA INTERFERENCE; TANDEM MASS SPECTROMETRY; TIME FACTOR; TUMOR CELL LINE; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HEK293 CELLS; HUMANS; MICRORNAS; NEOPLASTIC STEM CELLS; NEUROFILAMENT PROTEINS; PROTEOMICS; RNA INTERFERENCE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TIME FACTORS; TRANSFECTION; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 84923291240     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3061     Document Type: Article

References (69)

1. Zhu Y, Parada L.F. The molecular and genetic basis of neurological tumours. Nat Rev Cancer. 2002; 2(8):616-26.
2. Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol. 2009; 472:323-42.
3. Wen P Y, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507.
4. Prasad G, Sottero T, Yang X, Mueller S, James C D, Weiss W A, Polley M Y, Ozawa T, Berger M S, Aftab D T, Prados M D, Haas-Kogan D.A. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011; 13(4):384-92.
5. Lwin Z, MacFadden D, Al-Zahrani A, Atenafu E, Miller B A, Sahgal A, Menard C, Laperriere N, Mason W.P. Glioblastoma management in the temozolomide era: have we improved outcome? J Neurooncol. 2013; 115(2):303-10.
6. Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, Suzuki K, Hayashi K, Matsuo T, Kamada K, Nagata I, Yamashita S. miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett. 2010; 296(2):241-8.
7. Wong S T, Zhang X Q, Zhuang J T, Chan H L, Li C H, Leung G.K. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Res. 2012; 32(7):2835-41.
8. Wang L, Shi Z M, Jiang C F, Liu X, Chen Q D, Qian X, Li D M, Ge X, Wang X F, Liu L Z, You Y P, Liu N, Jiang B.H. MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget. 2014; 5(14):5416-27.
9. Chen J, Fu X, Wan Y, Wang Z, Jiang D,Shi L. miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. Tumour Biol. 2014; 35(7):6293-302.
10. She X, Yu Z, Cui Y, Lei Q, Wang Z, Xu G, Luo Z, Li G, Wu M. miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells. Med Oncol. 2014; 31(4):892.
11. She X, Yu Z, Cui Y, Lei Q, Wang Z, Xu G, Xiang J, Wu M, Li G. miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. Oncol Rep. 2014.
12. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97.
13. Formosa A, Markert E K, Lena A M, Italiano D, Finazzi-Agro E, Levine A J, Bernardini S, Garabadgiu A V, Melino G, Candi E. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 2013.
14. Chen B, Duan L, Yin G, Tan J, Jiang X. miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O. J Chemother. 2013; 25(4):229-38.
15. Rothschild S I, Tschan M P, Jaggi R, Fey M F, Gugger M, Gautschi O. MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma. J Thorac Oncol. 2012; 7(7):1069-77.
16. Liu L, Zou J, Wang Q, Yin F Q, Zhang W, Li L. Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer. Tumour Biol. 2014.
17. Tang H, Liu X, Wang Z, She X, Zeng X, Deng M, Liao Q, Guo X, Wang R, Li X, Zeng F, Wu M, Li G. Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. Brain Res. 2011; 1390:21-32.
18. Tang H, Wang Z, Liu Q, Liu X, Wu M, Li G. Disturbing miR-182 and -381 inhibits BRD7 transcription and glioma growth by directly targeting LRRC4. PLoS One. 2014; 9(1):e84146.
19. Xu Y, Ohms S J, Li Z, Wang Q, Gong G, Hu Y, Mao Z, Shannon M F, Fan J.Y. Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance. PLoS One. 2013; 8(11):e82062.
20. Leermakers F A, Zhulina E.B. How the projection domains of NF-L and alpha-internexin determine the conformations of NF-M and NF-H in neurofilaments. Eur Biophys J. 2010; 39(9):1323-34.
21. Macoska J A, Trybus T M, Benson P D, Sakr W A, Grignon D J, Wojno K D, Pietruk T, Powell I.J. Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res. 1995; 55(22):5390-5.
22. Knowles M A, Shaw M E, Proctor A.J. Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene. 1993; 8(5):1357-64.
23. Kang S, Kim B, Park S B, Jeong G, Kang H S, Liu R, Kim S.J. Stage-specific methylome screen identifies that NEFL is downregulated by promoter hypermethylation in breast cancer. Int J Oncol. 2013; 43(5):1659-65.
24. Coon S W, Savera A T, Zarbo R J, Benninger M S, Chase G A, Rybicki B A, Van Dyke D.L. Prognostic implications of loss of heterozygosity at 8p21 and 9p21 in head and neck squamous cell carcinoma. Int J Cancer. 2004; 111(2):206-12.
25. Chen B, Chen J, House M G, Cullen K J, Nephew K P, Guo Z. Role of neurofilament light polypeptide in head and neck cancer chemoresistance. Mol Cancer Res. 2012; 10(3):305-15.
26. Zhang WB, Wang Z, Shu F, Jin YH, Liu HY, Wang QJ, Yang Y. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem 2010;285:40461-40471.
27. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T. MTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009;15:5404-5413.
28. Haddad LA, Smith N, Bowser M, Niida Y, Murthy V, Gonzalez-Agosti C, Ramesh V. The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskeleton. J Biol Chem 2002;277:44180-44186.
29. Yang Y H, Morand E, Leech M. Annexin A1: potential for glucocorticoid sparing in RA. Nat Rev Rheumatol. 2013; 9(10):595-603.
30. Da Silva Pereira C C, Gattas G S, Lucato L.T. Alexander disease: a novel mutation in the glial fibrillary acidic protein gene with initial uncommon clinical and magnetic resonance imaging findings. J Comput Assist Tomogr. 2013; 37(5):698-700.
31. Banski P, Mahboubi H, Kodiha M, Shrivastava S, Kanagaratham C, Stochaj U. Nucleolar targeting of the chaperone hsc70 is regulated by stress, cell signaling, and a composite targeting signal which is controlled by autoinhibition. J Biol Chem. 2010; 285(28):21858-67.
32. Spiliotis E T, Kinoshita M,Nelson W.J. A mitotic septin scaffold required for Mammalian chromosome congression and segregation. Science. 2005; 307(5716):1781-5.
33. Achour O, Bridiau N, Kacem M, Delatouche R, Bordenave-Juchereau S, Sannier F, Thiery V, Piot J M, Maugard T, Arnaudin I. Cathepsin D activity and selectivity in the acidic conditions of a tumor microenvironment: Utilization in the development of a novel Cathepsin D substrate for simultaneous cancer diagnosis and therapy. Biochimie. 2013; 95(11):2010-7.
34. Shen H, Damcott C, Shuldiner S R, Chai S, Yang R, Hu H, Gibson Q, Ryan K A, Mitchell B D, Gong D.W. Genome-wide association study identifies genetic variants in GOT1 determining serum aspartate aminotransferase levels. J Hum Genet. 2011; 56(11):801-5.
35. Meola J, Hidalgo Gdos S, Silva J C, Silva L E, Paz C C, Ferriani R.A. Caldesmon: new insights for diagnosing endometriosis. Biol Reprod. 2013; 88(5):122.
36. Siemens H, Jackstadt R, Kaller M, Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 2013; 4(9):1399-415.
37. Asuthkar S, Velpula K K, Chetty C, Gorantla B,Rao J.S. Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget. 2012; 3(11):1439-54.
38. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284.
39. Wang N, Wang Z, Peng C, You J, Shen J, Han S, Chen J. Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via beta-catenin/ABCG2 signaling. Carcinogenesis 2014;35:2544-2554.
40. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2011;71:3196-3201.
41. Rasper M, Schafer A, Piontek G, Teufel J, Brockhoff G, Ringel F, Heindl S, Zimmer C, Schlegel J. Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. Neuro Oncol. 2010; 12(10):1024-33.
42. Pietras A, Katz A M, Ekstrom E J, Wee B, Halliday J J, Pitter K L, Werbeck J L, Amankulor N M, Huse J T, Holland E.C. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell. 2014; 14(3):357-69.
43. Chen L, Bourguignon LY. Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells. Mol Cancer 2014;13:52.
44. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008;283:17635-17651.
45. Opyrchal M, Salisbury JL, Iankov I, Goetz MP, McCubrey J, Gambino MW, Malatino L, Puccia G, Ingle JN, Galanis E, D'Assoro AB. Inhibition of Cdk2 kinase activity selectively targets the CD44(+)/CD24(-)/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells. Int J Oncol 2014;45:1193-1199.
46. Todd J R, Becker T M, Kefford R F, Rizos H. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells. Pigment Cell Melanoma Res. 2013; 26(4):518-26.
47. Hodi F S, Corless C L, Giobbie-Hurder A, Fletcher J A, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber J S, Gajewski T F, O'Day S J, Kim K B, Lawrence D, Flaherty K T, Luke J J, Collichio F A, Ernstoff M S, Heinrich M C, Beadling C, Zukotynski K A, Yap J T, Van den Abbeele A D, Demetri G D, Fisher D.E. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013; 31(26):3182-90.
48. Yang WT, Zheng PS. Promoter hypermethylation of KLF4 inactivates its tumor suppressor function in cervical carcinogenesis. PLoS One 2014;9:e88827.
49. Higgins D M, Wang R, Milligan B, Schroeder M, Carlson B, Pokorny J, Cheshier S H, Meyer F B, Weissman I L, Sarkaria J N, Henley J.R. Brain tumor stem cell multipotency correlates with nanog expression and extent of passaging in human glioblastoma xenografts. Oncotarget. 2013; 4(5):792-801.
50. Ding Y, Yu AQ, Li CL, Fang J, Zeng Y, Li DS. TALEN-mediated Nanog disruption results in less invasiveness, more chemosensitivity and reversal of EMT in Hela cells. Oncotarget 2014;5:8393-8401.
51. Zhou JJ, Deng XG, He XY, Zhou Y, Yu M, Gao WC, Zeng B, Zhou QB, Li ZH, Chen RF. Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression. Int J Oncol 2014;44:2034-2040.
52. He Q Z, Luo X Z, Zhou Q, Wang K, Li S X, Li Y, Zhu H T, Duan T. Expression of nestin in ovarian serous cancer and its clinicopathologic significance. Eur Rev Med Pharmacol Sci 2013; 17(21):2896-901.
53. Qin Q, Sun Y, Fei M, Zhang J, Jia Y, Gu M, Xia R, Chen S, Deng A. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer. Neoplasma. 2012; 59(3):310-5.
54. Piva M, Domenici G, Iriondo O, Rabano M, Simoes B M, Comaills V, Barredo I, Lopez-Ruiz J A, Zabalza I, Kypta R,Vivanco M. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med 2014; 6(1):66-79.
55. Sosnik A. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: A review. Adv Drug Deliv Rev. 2013; 65(13-14):1828-51.
56. Li W Q, Li Y M, Tao B B, Lu Y C, Hu G H, Liu H M, He J, Xu Y, Yu H.Y. Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med Sci Monit. 2010; 16(10):HY27-30.
57. Bleau A M, Hambardzumyan D, Ozawa T, Fomchenko E I, Huse J T, Brennan C W, Holland E.C. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009; 4(3):226-35.
58. Bronger H, Konig J, Kopplow K, Steiner H H, Ahmadi R, Herold-Mende C, Keppler D, Nies A.T. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res. 2005; 65(24):11419-28.
59. Kuan C T, Wakiya K, Herndon J E, 2nd, Lipp E S, Pegram C N, Riggins G J, Rasheed A, Szafranski S E, McLendon R E, Wikstrand C J, Bigner D.D. MRP3: a molecular target for human glioblastoma multiforme immunotherapy. BMC Cancer. 2010; 10:468.
60. Alexiou G A, Goussia A, Voulgaris S, Fotopoulos A D, Fotakopoulos G, Ntoulia A, Zikou A, Tsekeris P, Argyropoulou M I, Kyritsis A.P. Prognostic significance of MRP5 immunohistochemical expression in glioblastoma. Cancer Chemother Pharmacol. 2012; 69(5):1387-91.
61. Jin F, Zhao L, Zhao H Y, Guo S G, Feng J, Jiang X B, Zhang S L, Wei Y J, Fu R, Zhao J.S. Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance-associated protein genes. Neuroscience. 2008; 154(2):541-50.
62. Jeon H M, Sohn Y W, Oh S Y, Kim S H, Beck S, Kim S, Kim H. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res. 2011; 71(9):3410-21.
63. Irollo E, Pirozzi G. CD133: To be or not to be, is this the real question? Am J Transl Res 2013;5:563-581.
64. Sarvi S, Mackinnon AC, Avlonitis N, Bradley M, Rintoul RC, Rassl DM, Wang W, Forbes SJ, Gregory CD, Sethi T. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res 2014;74:1554-1565.
65. El-Khattouti A, Selimovic D, Haikel Y, Megahed M, Gomez CR, Hassan M. Identification and analysis of CD133(+) melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response. Cancer Lett 2014;343:123-133.
66. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, Prestegarden L, Rosland G, Thorsen F, Stuhr L, Molven A, Bjerkvig R, Enger PO. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008;122:761-768.
67. Warrier S, Pavanram P, Raina D, Arvind M. Study of chemoresistant CD133+ cancer stem cells from human glioblastoma cell line U138MG using multiple assays. Cell Biol Int 2012;36:1137-1143.
68. Wang R, Wang Z, Yang J, Liu X, Wang L, Guo X, Zeng F, Wu M,Li G. LRRC4 inhibits the proliferation of human glioma cells by modulating the expression of STMN1 and microtubule polymerization. J Cell Biochem. 2011; 112(12):3621-9.
69. Tang H, Wang Z, Liu X, Liu Q, Xu G, Li G, Wu M. LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway. Curr Cancer Drug Targets. 2012; 12(8):1032-42.